AC Immune: Funding, Investors & Team (Sep 2026)
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They have three products currently undergoing clinical trials, with a specific focus on neurodegenerative diseases. The company's primary goal is to create and develop therapeutic and diagnostic products that can both prevent and modify diseases caused by misfolding proteins. AC Immune utilizes two distinct technology platforms to create antibodies, small molecules, and vaccines for a wide range of neurodegenerative indications.
AC Immune has raised $54.1M across 2 funding rounds on record, the most recent an undisclosed round of $4.0M announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
AC Immune Company Profile and Key Stats
Latest funding round on record: Jun 2026.
AC Immune Funding Rounds
AC Immune raised $50.1M in an undisclosed round announced in Dec 2023.
2.5 years later, an undisclosed round of $4.0M was announced in Jun 2026.
AC Immune Founders and Leadership Team
No contact details are on record for this team yet.
AC Immune Funding Compared to Other Biotechnology Startups
AC Immune's latest round of $4.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like AC Immune in Biotechnology and Lausanne
Companies Similar to AC Immune
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Pharvaris is a clinical-stage company working on bringing a new oral bradykinin B2 receptor antagonist to…
AC Immune Funding FAQs
What does AC Immune do?
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They have three products currently undergoing clinical trials, with a specific focus on neurodegenerative diseases. The company's primary goal is to create and develop therapeutic and diagnostic products that can both prevent and modify diseases caused by misfolding proteins. AC Immune utilizes two distinct technology platforms to create antibodies, small molecules, and vaccines for a wide range of neurodegenerative indications.
How much funding has AC Immune raised?
AC Immune has raised $54.1M across 2 rounds on record. The most recent is an undisclosed round of $4.0M announced in Jun 2026.
When did AC Immune last raise funding?
AC Immune's most recent funding round on record is an undisclosed round of $4.0M, announced in Jun 2026.
Who is the CEO of AC Immune?
Andrea Pfeifer is listed as CEO at AC Immune.
Where is AC Immune headquartered?
AC Immune is based in Lausanne, Vaud, Switzerland.
How many employees does AC Immune have?
AC Immune is in the 101-250 employee band.
How does AC Immune's funding compare to other Biotechnology startups?
AC Immune's latest round of $4.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's AC Immune Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for AC Immune is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.